The capital infusion aids the company’s commercialization efforts for its AI-driven surgical navigation platform in the U.S. and overseas.
Seattle-based Proprio designed its Paradigm surgical navigation platform to replace traditional surgical navigation technologies. Using an advanced approach, it avoids the pitfalls that pull attention away from the patient and disrupt workflows. FDA cleared Paradigm in April.
The system uses light field technology and AI to generate a real-time, 3D visualization of surgery. It provides surgeons with the Proprio Volumetric Intelligence, which combines medical images with live data from Paradigm’s sensor suite.
Proprio says its Paradigm system eliminates the need for intraoperative scans, reducing radiation exposure. This saves up to 30 minutes per procedure, too. By quickly registering imaging data to the anatomy within surgical workflows, the system delivers accuracy and enables surgeons to maintain focus.
The Paradigm system can collect “a tremendous amount of surgical data,” according to a news release. This can hep develop many applications that go beyond the status quo approaches to surgery.
“We are just beginning to reveal the potential applications of Proprio’s technology and data,” said Gabriel Jones, CEO and co-founder of Proprio. “This investment arrives at a pivotal moment, as we perform our first-in-human cases and bring Paradigm to patients around the world. Together, these milestones are a testament to the unparalleled capabilities of the Proprio Paradigm and its potential to revolutionize surgery.”
